These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37883007)

  • 1. Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan.
    Iwasaki K; Wakabayashi H; Saiki A; Ueshiba H; Murakami Y; Matsuzawa Y
    Drugs Real World Outcomes; 2024 Mar; 11(1):43-52. PubMed ID: 37883007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study.
    Oishi K; Hirano T; Murata Y; Hamada K; Uehara S; Suetake R; Yamaji Y; Asami-Noyama M; Edakuni N; Ohata S; Utsunomiya T; Sakamoto K; Onoda H; Matsumoto T; Matsunaga K; Yano M
    Ther Adv Respir Dis; 2019; 13():1753466619872890. PubMed ID: 31476961
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.
    Sugino K; Ono H; Watanabe N; Ando M; Tsuboi E; Homma S; Kishi K
    BMC Pulm Med; 2021 Jul; 21(1):218. PubMed ID: 34246227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis.
    Wright WA; Crowley LE; Parekh D; Crawshaw A; Dosanjh DP; Nightingale P; Thickett DR
    BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33771813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
    Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
    Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
    Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
    PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly.
    Honda K; Saraya T; Ishii H
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis.
    Huh JY; Lee JH; Song JW
    Front Pharmacol; 2023; 14():1301923. PubMed ID: 38192410
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.
    Adams CJ; Shapera S; Ryerson CJ; Assayag D; Johannson KA; Fell CD; Morisset J; Manganas H; Kolb M; Hambly N; Cox G; Khalil N; Marcoux V; Wilcox PG; To T; Sadatsafavi M; Halayko AJ; Gershon A; Garlick K; Fisher JH
    Respir Med; 2022 Jan; 191():106722. PubMed ID: 34959146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.
    Inomata M; Nishioka Y; Azuma A
    Core Evid; 2015; 10():89-98. PubMed ID: 26346347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
    Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
    Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.